The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hyperplasia Without Atypia: A Cohort Study

Not yet recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

May 31, 2025

Conditions
Endometrial Hyperplasia Without Atypia
Interventions
DRUG

Etonogestrel implant

The etonogestrel implant will be inserted on the inner side of the non-dominant upper arm of the patient. Three months after insertion, a repeat transvaginal ultrasound will be performed to document endmetrial thickness and an endometrial biopsy will also be done using the Pipelle to document the histology of the endometrium. If the biopsy showed regression of the hyperplasia, the implant will be left in place for a minimum of 12 months until 3 years. If the repeat biopsy showed non-resolution of the hyperplasia, the patient will be referred to a gynecologic oncologist for further management

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Organon

INDUSTRY

lead

University of the Philippines

OTHER

NCT06378489 - The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hyperplasia Without Atypia: A Cohort Study | Biotech Hunter | Biotech Hunter